期刊
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
卷 65, 期 5, 页码 443-455出版社
SPRINGER
DOI: 10.1007/s00228-009-0622-y
关键词
Pharmacokinetics; Levodopa; Carbidopa; Entacapone; Parkinson's disease
资金
- Orion Corporation Orion Pharma and Novartis Pharmaceuticals AG
To compare plasma levodopa concentrations after repeated doses of levodopa/carbidopa/entacapone (LCE) and levodopa/carbidopa (LC). Open-label, randomized, two-period, active-controlled, cross-over study with four dosing regimens: groups I and II (healthy volunteers and Parkinson's disease patients) received levodopa 100 mg or 150 mg four times daily, respectively, and groups III and IV (healthy volunteers) received the same strengths of levodopa five times daily. Pharmacokinetic (PK) parameters determined for levodopa included C(min), C(max), C(max) -aEuro parts per thousand C(min), AUC, t(1/2), and t(max). In healthy volunteers and PD patients, mean trough levels (C(min)), C(max), and AUC of levodopa were, in general, significantly higher during LCE compared to LC administration. Compared to C(min), C(max), and AUC, differences between the treatments in variability of levodopa concentrations (C(max) -aEuro parts per thousand C(min)) were less consistent. The present results on the differences in levodopa PK between LCE and LC provide a basis to evaluate the relationship of levodopa PK and the induction of motor complications in an on-going study in early Parkinson's disease using similar dosing regimens.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据